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then released. There were no findings of changes in the position of
the device until the end of surgery.
Ahead of waking from anesthesia, remifentanil and desflurane
were discontinued. Prior to sugammadex administration, ECG
monitoring showed tachycardia (Figure 3A) and we considered
that the arrhythmia was an indication of ASO dislodgement.
Transthoracic echocardiography (TTE) confirmed that the device
was located in the right atrium (Figure 2B). General anesthesia
with propofol and remifentanil was reintroduced, along with rocu-
ronium to maintain muscle relaxation. Transcatheter removal of
the device was subsequently performed with no adverse event.
The patient recovered well from the procedure and requested a
repeat transcatheter approach. A second transcatheter ASD closure
with an ASO was scheduled. As the cause of the first device
dislodgement may have been hemodynamic changes, such as
temporary elevation of blood pressure during recovery from seda-
tion, we planned to continue low dose anesthetic administration
until extubation to stabilize the patient’s hemodynamics.
Defect closure was performed for the second time 2 months after
the first. Anesthesia was maintained with 3-4 mg/kg/h propofol
instead of desflurane (Figure 1B). We attempted to position a 34
mm Amplatzer device, but this appeared to be too large, pushing
the posterior heart wall, so a 32 mm ASO device was again selected.
Positioning was monitored by TEE and ICE before finally being
Figure1. Anesthetic records
A : Anesthetic record of the first transcatheter ASD closure. There were some blanks in blood pressure paragraph because of an omission.
B : Anesthetic record of the second transcatheter ASD closure. After the extubation, tachycardia occurred with HR over 140/min.
BP = blood pressure, HR = heart rate.
A slash mark indicate to end the administration of each medication.
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released (Figure 2C). The dose of propofol and remifentanil was
maintained at 10 mg/h and 0.09 µg/kg/h, respectively, after
completion of the procedure to extubation. Sugammadex was
administered and the patient was extubated ; then, ECG monitor-
ing showed nonsustained ventricular tachycardia (Figure 3B).
TTE detected the ASO device in the pulmonary artery (Figure 2D).
Anesthesia was reintroduced and reintubation was conducted. The
device was retrieved under transcatheter management.
We concluded that transcatheter ASD closure in this patient was
too challenging and surgical ASD was conducted by cardiac sur-
geons in our hospital 4 months later after the second transcatheter
ASD closure. Surgery was completed successfully and the patient
continues to do well.
DISCUSSION
The first report of a transcatheter ASD closure was published by
King andMillis in 1976 (3). Transcatheter approaches have proved
to be as effective as surgical ASD closure, and offer significant
benefits in terms of low invasiveness, shorter hospitalization, and
fewer complications (4). In a comparison of outcomes following
transcatheter and surgical ASD closure, Du et al reported a proce-
dural attempt success rate, complication rate, and mean length of
hospital stay of 95.7%, 7.2%, and 1.00.3 days for patients in the
device group versus 100%, 24.0%, and 3.41.2 days for the surgical
group (5). However, there are a number of complications associ-
ated with transcatheter ASD closure, such as heart wall erosion,
cardiac perforation, arrhythmia, and device dislodgement (1).
Figure2. Echograms during the transcatheter ASD closure procedure
A : TEE image indicates the implantation device holding the IAS at the first time procedure.
B : TTE image indicates the dislodgement device in the right atrium at the first time procedure.
C : TEE image indicates the implantation device holding the IAS at the second time procedure.
D : TTE image indicates the dislodgement device in the pulmonary artery at the second time procedure.
Ao = aorta, ASO = Amplatzer Septal Occluder, IAS = interatrial septum, LA = leftatrium, LV = left ventricle, mPA = main pulmonary artery, RA = right
atrium, RV = right ventricle, rPA = right pulmonary artery.
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Device dislodgement may cause valvular disease with rupture of
the chordae tendinae or device embolization, and subsequent
heart failure or infarction can prove fatal. Previous studies have
shown the rate of device dislodgement to be 0.5-5.5% (1, 6), gener-
ally occurring in the first 24 hours after the procedure (5). However,
dislodgement may also occur many years after the intervention.
Lee et al reported that a Qp/Qs ratio3.13, interatrial septum
erosion, and floppiness or aneurysm formation post- implantation
may be predictors of ASO dislodgement in adults and children
(7). In particular, high Qp/Qs ratios may be related to greater
changes in intracardiac pressure, which affects device imbalance.
Other reports have shown that ASD size, superior posterior rim or
aortic rim deficiency, and septal rim length5 mm may also be
predictors of possible device dislodgement. Ueda et al reported
that transcatheter closure in patients with relatively large ASDs, a
poor aortic rim, and an inferoposterior rim5 mm was associated
with greater procedural difficulty and required a longer procedure
time (8).
In another report, ST elevation in V1-V5 was seen in a patient
with dislodgement of the ventricular septal occluder device (9).
DiBardino et al also noted that a secondary arrhythmia, such as
NSVT, atrial flutter, and premature ventricular contraction, occurred
with embolization (1). The arrhythmia and other ECG changes are
often the ‘warning sign’ of an adverse event. On the other hand, the
arrhythmia can induce the device dislodgement and subsequent
embolization in itself.
In our case, we experienced repeated device dislodgement in an
adult patient undergoing transcatheter ASD closure with an ASO.
The Qp/Qs ratio was 5.6, ASD size was 29 mm, and inferoposterior
rim was5 mm, factors that could have predicted a high risk of
device dislodgement. On both attempts, dislodgement occurred
during recovery from general anesthesia, suggesting that this
period poses a particularly high risk. At recovery from anesthesia,
hemodynamics can be unstable. In most cases, blood pressure and
heart rate will rise due to the end of anesthetic administration
suppressing cardiac output and vascular resistance or the activation
of the sympathetic nervous system with awakening. Hemodynamic
changes may affect the ASO device stability, and result in the
device dislodgement. However, attempting to decrease hemody-
namic changes during recovery from general anesthesia is un-
likely to result in a reduced incidence of device dislodgement as
hemodynamic changes also occur during exercise and stimulation in
daily life. In both transcatheter ASD closure attempts, the tachycar-
diac arrhythmia possibly indicated the devise dislodgement. The
12- lead ECGmonitor may have been useful to notice the arrhyth-
mia immediately.
Minimizing the risk of complications is dependent on careful
case selection, size of the defect, use of the appropriately sized
device, and TEE monitoring during the transcatheter procedure.
In addition, it is important that anesthesiologists, cardiologists, and
cardiac surgeons anticipate the risk of device dislodgement, par-
ticularly during deployment and emergence from anesthesia, and
plan appropriate treatment strategies in advance. In high-risk
cases, we should monitor the patient’s cardiovascular status con-
stantly.
CONCLUSIONS
In this case, we experienced the repeated dislodgement of an
ASO device during emergence from general anesthesia in a patient
undergoing transcatheter ASD closure. We suggest that the risk of
device dislodgement should be anticipated in advance of surgery
and that the cardiovascular status of high-risk patients should be
monitored continuously during the procedure.
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